GFH 276
Alternative Names: GFH-276Latest Information Update: 20 Jan 2025
Price :
$50 *
At a glance
- Originator GenFleet Therapeutics
- Class Antineoplastics
- Mechanism of Action Cyclophilin A modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Jan 2025 GenFleet has patent pending for GFH 276
- 20 Jan 2025 GenFleet Therapeutics announces intention to submit IND application to National Medical Products Administration for Solid tumours (PO) in the first half of 2025
- 20 Jan 2025 Pharmacokinetics and pharmacodynamics data from a Preclinical trial in Solid tumours released by GenFleet Therapeutics before January 2025